lung neoplasm
Enable an AI agent to distinguish a lung neoplasm from its mimics, represent its supported biological and clinical state, and identify evidence needed for appropriate clinical review.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 18 findings · 28 questions
Pulmonary lesion identity Establish what pulmonary finding is being modeled and whether its neoplastic nature is supported.
Neoplasm versus mimic
Separate the observed abnormality from the interpretation that it is neoplastic.
Basis for neoplastic identification
Record the evidence and certainty behind identifying this finding as a lung neoplasm.
- What evidence supports a neoplasm rather than an infectious, inflammatory or other non-neoplastic pulmonary finding? definition
- Which report establishes the current diagnostic status, and does it describe suspicion, confirmation or unresolved uncertainty? provenance
Anatomical localization
Identify the lesion's pulmonary location and boundaries with adjacent compartments.
Pulmonary site and lesion matching
Maintain a stable lesion identity across reports, images and specimens.
- Which side, lobe and segment contain the lesion, and what is its relationship to the bronchi and pleura? measurement
- What evidence distinguishes a pulmonary origin from extension of a pleural, mediastinal or chest-wall tumor? boundary
Origin and tumor classification Represent where the neoplasm arose and how its biological identity has been classified.
Primary versus secondary
Assess pulmonary origin and relationships to other tumors.
Origin and relationship to other lesions
Capture the supported interpretation of origin without inferring it from location alone.
- What clinical, morphological or molecular evidence supports primary pulmonary origin versus metastasis from another organ? provenance
- If multiple tumors are present, what supports treating them as independent primaries or related deposits? boundary
Behavior and histology
Preserve the reported behavior and pathological classification.
Supported pathological classification
Record tumor type and behavior at the specificity justified by available material.
- What tumor type and behavior are reported, and which classification and edition supply those terms? definition
- Does the specimen support the stated subtype and any invasion or grade assessment, or does the report qualify them? boundary
Diagnostic material and markers Connect tissue, cytology and other test results to their sampled targets and interpretive limits.
Sampling and representativeness
Track which lesion or site was sampled and whether material was adequate.
Specimen-to-lesion link
Relate diagnostic material to the pulmonary lesion or associated disease site.
- Which pulmonary lesion, lymph node or other site produced the specimen, and when was it collected relative to treatment? provenance
- What limitations in adequacy, tumor content or sampling restrict the conclusions, especially for a negative or nondiagnostic result? boundary
Ancillary characterization
Represent immunophenotypic, molecular and protein-marker evidence in context.
Assay-specific marker interpretation
Preserve marker results and their stated diagnostic or clinical relevance.
- Which markers were assessed, by which assays and on which specimens, and what exact results and adequacy statements were reported? measurement
- What evidence supports each marker's interpretation for this tumor type, and which unresolved results require specialist review? action
Extent and pulmonary effects Describe anatomical spread and attributable effects on pulmonary structures.
Distribution and stage
Record local, nodal and distant findings under an applicable framework.
Supported extent assessment
Separate observed or suspected involvement from the resulting stage assignment.
- Which local structures, nodal stations and distant sites are involved or suspected, and what evidence supports each assessment? provenance
- Does a staging system apply to this tumor, and what system, edition, date and clinical or pathological basis underlie the recorded stage? boundary
Local pulmonary consequences
Represent effects on airways, lung tissue and adjacent structures without presuming causation.
Lesion-attributable effects
Link documented obstruction, collapse, bleeding or other effects to the lesion with appropriate certainty.
- What airway obstruction, atelectasis, bleeding or adjacent-structure involvement is documented, and how confidently is it attributed to this neoplasm? measurement
- Which documented consequences have an existing clinical escalation or follow-up instruction that an agent should surface? action
Longitudinal course and review Track comparable observations, treatment context and unresolved interpretations over time.
Serial lesion assessment
Compare the same lesion across dated observations.
Comparable size and composition change
Preserve measured changes and the limits of cross-study comparison.
- How have lesion dimensions, volume when available, and solid or ground-glass components changed between specified examinations? measurement
- Are lesion matching, imaging technique and measurement method sufficiently comparable to support the stated change? boundary
Post-intervention interpretation
Connect observed course to treatment history and the next documented review.
Residual, recurrent or treatment-related finding
Distinguish supported disease assessments from unresolved post-treatment abnormalities.
- What evidence distinguishes viable residual or recurrent neoplasm from scar, inflammation or other treatment-related change? boundary
- What clinician-documented review or evidence-gathering step addresses the remaining uncertainty, and when is it due? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these standards and regulation hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of lung neoplasm this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.LIV
- Other names and narrower kinds
- lung benign neoplasm, pulmonary sulcus neoplasm, lung germ cell tumor, lung clear cell-sugar-tumor, hilar lung neoplasm, Langerhans cell histiocytosis in childhood and adulthood
What it is Filled
A lung neoplasm is an abnormal proliferation of cells forming a tumour in the lung, encompassing benign and malignant growths that may originate there or spread there from another primary site.
In scope
- Suspected or established neoplasms involving pulmonary tissue, with diagnostic certainty recorded
- Benign, in situ, malignant and uncertain-behavior classifications when supported by evidence
- Primary pulmonary origin versus metastatic involvement from another site
- Lesion-level anatomy, pathology, molecular characterization and relationships among multiple lesions
- Disease extent, longitudinal observations and lesion-related consequences
- Evidence dependencies and unresolved distinctions that affect clinical interpretation
Out of scope
- Non-neoplastic pulmonary nodules, infections and inflammatory lesions except as differential diagnoses
- Primary pleural, mediastinal and chest-wall neoplasms except for their relationship to lung involvement
- The complete model of an extrapulmonary primary cancer
- Patient-wide fitness, comorbidities, preferences and care decisions
- Population screening programs and exposure epidemiology
- Detailed models of imaging equipment, biopsy procedures and treatment regimens
Why it exists Filled
Enable an AI agent to distinguish a lung neoplasm from its mimics, represent its supported biological and clinical state, and identify evidence needed for appropriate clinical review.
Distinguishing features Filled
- A pulmonary nodule or mass is an imaging finding; its appearance alone does not establish that it is a neoplasm.
- Lung neoplasm is broader than lung cancer: the model must distinguish neoplastic behavior rather than presume malignancy.
- A tumor originating in pulmonary tissue differs from an extrapulmonary tumor metastatic to the lung, even when both occupy the same lung region.
- A pleural or mediastinal tumor extending into the lung differs from a primary pulmonary neoplasm; the site of origin must be supported separately from the sites involved.
- Multiple pulmonary lesions may represent independent neoplasms, related tumor deposits or a mixture of neoplastic and non-neoplastic findings; multiplicity alone does not settle their relationship.
What robots and AI may and may not do Filled
Must not
- Diagnose or rule out a lung tumour in a specific person.
- Recommend, start or stop treatment for a person.
- Share a patient's diagnosis or images without consent or legal basis.
- Blame a patient for their illness or stigmatise them because of smoking history.
- Promote unproven cures as alternatives to medical care.
Only with a human decision
- Telling a person or family about a diagnosis or prognosis.
- Any decision about investigation, surgery or treatment.
May
- Explain what lung neoplasms are in general terms, citing medical sources.
- Support clinicians by summarising records and guidelines they have access to.
- Encourage a person with symptoms to see a doctor.
Moral aspects Filled
- A diagnosis changes a life, and must be given by a clinician with care and accuracy.
- Lung cancer carries stigma linked to smoking that can deter people from seeking help.
Who is affected
- Patients
- Families and carers
- Clinicians
Owners Filled
Steward
The treating clinician answers for each case; the patient owns their health information.
Master systems
- Cancer registries
- Patient health records
Links to other meta-models Filled
parent
- Q3392853 - registry parent class
- Q58833963 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.lung-neoplasm
- Wikidata: Q15124212 (https://www.wikidata.org/wiki/Q15124212)
Direct properties required Filled
- Neoplasm identification status: suspected | established | indeterminate | excluded; evidence and date attached
- Pulmonary location: side, lobe, segment when known, central or peripheral position, and airway relationship
- Neoplastic behavior: benign | in situ | malignant | uncertain or unspecified behavior, using the cited classification
- Tumor origin: primary pulmonary | secondary from an identified primary | secondary from an unknown primary | unresolved
- Histopathological classification: reported tumor family, type, subtype and grade where applicable, with classification edition
- Lesion dimensions: mm for reported dimensions; mm³ for volume when available; method and date required
- Imaging composition: reported solid, part-solid, ground-glass or other appearance, including measured solid component when applicable
- Molecular and protein-marker results: marker-specific result, assay, specimen, adequacy, date and interpretation; not tested distinguished from negative
- Disease extent: local involvement, regional nodes and distant involvement; applicable stage with system, edition, date and clinical or pathological basis
- Relationship among lesions: independent primary | related deposit | direct extension | unresolved, with supporting evidence
- Observed course: newly observed | stable | growing | regressing | recurrent | indeterminate, with comparison interval and assessment method
Recognition required Filled
- Chest imaging may reveal a persistent focal nodule or mass, although infection and scarring can produce similar appearances.
- Irregular or spiculated margins can raise suspicion for malignancy but do not establish a neoplasm by themselves.
- Microscopic tissue examination can reveal a neoplastic cell population and its architecture, helping distinguish a tumour from reactive changes.
Capabilities and actions required Filled
- Assemble lesion-specific imaging, pathology and clinical evidence while preserving uncertainty and provenance.
- Compare serial observations and flag uncertain lesion matching or incompatible measurement methods.
- Identify missing evidence needed to distinguish a primary pulmonary neoplasm, metastasis and non-neoplastic mimic.
- Check whether a recorded classification, stage or biomarker interpretation applies to the documented tumor type.
- Prepare a clinician-review summary of extent, local effects, observed change and unresolved findings.
Hazards and failure modes required Filled
- A missed or delayed diagnosis lets a malignant tumour progress.
- A false alarm causes distress and invasive tests.
Standards and interfaces required Filled
- WHO Classification of Tumours, World Health Organization International Agency for Research on Cancer.
Context of use required Filled
- Lung neoplasms are encountered in respiratory medicine, radiology, pathology and oncology during investigation of symptoms or incidental imaging findings.
- The term supports documentation and assessment of abnormal lung growths before their origin and benign or malignant nature are fully established.
Sources Filled
- Wikidata item Q15124212: lung neoplasm - identity and sense of the item
- Wikipedia: Lung tumor - general description of the item
Open questions
- Does the registry intend lung neoplasm to include secondary pulmonary deposits and benign tumors, and what authoritative terminology mapping should establish that boundary?
- Does an existing Vercy world model already own this concept or its core tumor behavior, requiring linkage rather than a duplicate publication?
- Which pathology classifications and staging systems, with their editions, should govern the different pulmonary tumor families?
- What evidence standards should govern linking multiple pulmonary lesions to one neoplasm versus representing independent primary tumors?
- Which tumor-specific testing, longitudinal assessment and clinical review standards should be researched before this structural draft becomes a sourced publication?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q15124212/spec.json